Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: Time to Revisit Old Assumptions

2026/04/21 by Akshaya Jayachandran, Raad Chowdhury · 1 voice
Medicine · Biochemistry, Genetics and Molecular Biology · #Renal Transplantation Outcomes and Treatments #Renal Diseases and Glomerulopathies #Amyloidosis: Diagnosis, Treatment, Outcomes

paper · pdf · doi:10.1016/j.ekir.2026.106557

openalex publication_date 2026/04/21 · openalex created_date 2026/04/22 · openalex updated_date 2026/07/23

Abstract

The article by, Heybeli et al.1 in Kidney International Reports provides an important synthesis of the available literature on kidney transplant outcomes in monoclonal immunoglobulin deposition disease (MIDD). This review revisits a long-standing clinical dilemma— in the modern era of effective clone-directed therapy, should kidney transplantation still be approached with the same degree of caution?

Discussions

• #Kidney #Transplantation in Monoclonal #Imunoglobulin Deposition Disease: Time to Revisit Old Assumptions https://doi.org/10.1016/j.ekir.2026.106557 Original Article: https://doi.org/10.1016/j.ekir [bsky, 1 points, 0 comments]

Related

• Living Donor Kidney Transplantation in High-Recurrence Kidney Diseases: Precision Risk Stratification and Management
• Incidence, risk factors, treatment, and consequences of antibody‐mediated kidney transplant rejection: A systematic review
• Promoting Equity in Transplant Research by Addressing the Exclusion of Patients With Glomerular Disease
• Management of monoclonal gammopathy of renal significance: treatment standard
• IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody